|  Help  |  About  |  Contact Us

Publication : SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.

First Author  Corbett KS Year  2020
Journal  Nature Volume  586
Issue  7830 Pages  567-571
PubMed ID  32756549 Mgi Jnum  J:297398
Mgi Id  MGI:6472579 Doi  10.1038/s41586-020-2622-0
Citation  Corbett KS, et al. (2020) SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586(7830):567-571
abstractText  A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have led to the development of mutations that stabilize Betacoronavirus spike proteins in the prefusion state, improving their expression and increasing immunogenicity(1). This principle has been applied to design mRNA-1273, an mRNA vaccine that encodes a SARS-CoV-2 spike protein that is stabilized in the prefusion conformation. Here we show that mRNA-1273 induces potent neutralizing antibody responses to both wild-type (D614) and D614G mutant(2) SARS-CoV-2 as well as CD8(+) T cell responses, and protects against SARS-CoV-2 infection in the lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a phase III trial to evaluate its efficacy.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

3 Bio Entities

0 Expression